Circulating vaspin and visfatin are not affected by acute or chronic energy deficiency or leptin administration in humans

European Journal of Endocrinology

Volumn 164, Issue 6, 2011, Pages 911-917

  Kang, Eun Seok ^a,b   Magkos, Faidon ^a   Sienkiewicz, Elizabeth ^a   Mantzoros, Christos S ^a,c,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; LEPTIN; METRELEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLACEBO; RECOMBINANT LEPTIN; UNCLASSIFIED DRUG; VASPIN;

ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ENDOCRINE DISEASE; ENERGY METABOLISM; FEMALE; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; HYPOLEPTINEMIA; IN VIVO STUDY; MALE; OBESITY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STARVATION; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; BODY MASS; DRUG BLOOD LEVEL; DRUG EFFECT; HORMONE SUBSTITUTION; HYPOTHALAMIC AMENORRHEA; HYPOTHALAMUS DISEASE; NEUROENDOCRINE SYSTEM; PROTEIN MALNUTRITION;

ADULT; AMENORRHEA; DOUBLE-BLIND METHOD; ENERGY INTAKE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXERCISE; FASTING; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOTHALAMIC DISEASES; LEPTIN; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SERPINS; YOUNG ADULT;

EID: 79957670762     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0052     Document Type: Article

References (43)

1. Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P & Mikhailidis DP. Should adipokines be considered in the choice of the treatment of obesity-related health problems? Current Drug Targets 2010 11 122-135. (doi:10.2174/138945010790030992)
2. Wozniak SE, Gee LL, Wachtel MS & Frezza EE. Adipose tissue: the new endocrine organ? A review article Digestive Diseases and Sciences 2009 54 1847-1856. (doi:10.1007/s10620-008-0585-3)
3. Hida K,Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H & Kanwar YS. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. PNAS 2005 102 10610-10615. (doi:10.1073/pnas.0504703102)
4. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y & Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005 307 426-430. (doi:10.1126/science.1097243)
5. El-Mesallamya HO, Kassema DH, El-Demerdashb E & Aminc AI. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2011 60 63-70. (doi:10.1016/j.metabol.2010.04.008)
6. Rasouli N & Kern PA. Adipocytokines and the metabolic complications of obesity. Journal of Clinical Endocrinology and Metabolism 2008 93 S64-S73. (doi:10.1210/jc.2008-1613)
7. Rajala MW & Scherer PE. The adipocyte. At the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003 144 3765-3773. (doi:10.1210/en.2003-0580)
8. Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza CG & Mantzoros CS. Leptin in human physiology and therapeutics. Frontiers in Neuroendocrinology 2010 31 377-393. (doi:10.1016/j.yfrne.2010.06.002)
9. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A & Mantzoros CS. Recombinant human leptin in women with hypothalamic amenorrhea. New England Journal of Medicine 2004 351 987-997. (doi:10.1056/NEJMoa040388)
10. Lee JH, Chan JL, Sourlas E, Raptopoulos V & Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. Journal of Clinical Endocrinology and Metabolism 2006 91 2605-2611. (doi:10.1210/jc.2005-1545)
11. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P & Garg A. Leptin-replacement therapy for lipodystrophy. New England Journal of Medicine 2002 346 570-578. (doi:10.1056/ NEJMoa012437)
12. Rosenbaum M, Nicolson M, Hirsch J, Murphy E, Chu F & Leibel RL. Effects of weight change on plasma leptin concentrations and energy expenditure. Journal of Clinical Endocrinology and Metabolism 1997 82 3647-3654. (doi:10.1210/jc.82.11.3647)
13. Gonzalez CR, Caminos JE, Vazquez MJ, Garces MF, Cepeda LA, Angel A, Gonzalez AC, Garcia-Rendueles ME, Sangiao- Alvarellos S, Lopez M, Bravo SB, Nogueiras R & Dieguez C. Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. Journal of Physiology 2009 587 3741-3750. (doi:10.1113/jphysiol.2009.172510)
14. Tan BK, Chen J, Brown J, Adya R, Ramanjaneya M, Menon V, Bailey CJ, Lehnert H & Randeva HS. In vivo and ex vivo regulation of visfatin production by leptin in human and murine adipose tissue: role of mitogen-activated protein kinase and phosphatidyl-inositol 3-kinase signaling pathways. Endocrinology 2009 150 3530-3539. (doi:10.1210/en.2008-1655)
15. Chan JL, Wong SL & Mantzoros CS. Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity. Clinical Pharmacokinetics 2008 47 753-764. (doi:10.2165/00003088-200847110-00006)
16. Chan JL, Wong SL, Orlova C, Raciti P & Mantzoros CS. Pharmacokinetics of recombinant methionyl human leptin after subcutaneous administration: variation of concentration-dependent parameters according to assay. Journal of Clinical Endocrinology and Metabolism 2007 92 2307-2311. (doi:10. 1210/jc.2006-2864)
17. Wong SL, DePaoli AM, Lee JH & Mantzoros CS. Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates. Journal of Clinical Endocrinology and Metabolism 2004 89 2672-2677. (doi:10.1210/jc.2003-031931)
18. Chan JL, Heist K, DePaoli AM, Veldhuis JD & Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. Journal of Clinical Investigation 2003 111 1409-1421. (doi:10.1172/JCI200317490)
19. Chan JL, Matarese G, Shetty GK, Raciti P, Kelesidis I, Aufiero D, De Rosa V, Perna F, Fontana S & Mantzoros CS. Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. PNAS 2006 103 8481-8486. (doi:10.1073/pnas.0505429103)
20. Chou SH, Chamberland JP, Liu X, Matarese G, Gao C, Stefanakis R, Brinkoetter MT, Gong H, Arampatzi K & Mantzoros CS. Leptin is an effective treatment for hypothalamic amenorrhea: a randomized, double-blinded, placebo-controlled trial. PNAS 2011 In press. (doi:10.1073/pnas.1015674108)
21. Botella-Carretero JI, Luque-Ramirez M, Alvarez-Blasco F, Peromingo R, San Millan JL & Escobar-Morreale HF. The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery. Obesity Surgery 2008 18 1000-1006. (doi:10.1007/s11695-007-9369-7)
22. Krzyzanowska K, Mittermayer F, Krugluger W, Kopp HP & Schernthaner G. Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity 2006 14 1886-1889. (doi:10. 1038/oby.2006.219)
23. Handisurya A, Riedl M, Vila G, Maier C, Clodi M, Prikoszovich T, Ludvik B, Prager G, Luger A & Kautzky-Willer A. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obesity Surgery 2010 20 198-203. (doi:10. 1007/s11695-009-9882-y)
24. Ingelsson E, Larson MG, Fox CS, Yin X, Wang TJ, Lipinska I, Pou KM, Hoffmann U, Benjamin EJ, Keaney JF Jr & Vasan RS. Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care 2007 30 1278-1280. (doi:10.2337/dc06-2353)
25. Mantzoros CS. Role of leptin in reproduction. Annals of the New York Academy of Sciences 2000 900 174-183. (doi:10.1111/j.1749-6632.2000.tb06228.x)
26. Rosenbaum M, Sy M, Pavlovich K, Leibel RL & Hirsch J. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. Journal of Clinical Investigation 2008 118 2583-2591. (doi:10.1172/JCI35055)
27. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos- Flier E & Flier JS. Role of leptin in the neuroendocrine response to fasting. Nature 1996 382 250-252. (doi:10.1038/382250a0)
28. Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A,Weimer L, Heymsfield S, Gallagher D, Mayer L, Murphy E & Leibel RL. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. Journal of Clinical Investigation 2005 115 3579-3586. (doi:10.1172/JCI25977)
29. Kim YB, Uotani S, Pierroz DD, Flier JS & Kahn BB. In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues: overlapping but distinct pathways from insulin. Endocrinology 2000 141 2328-2339. (doi:10.1210/en.141.7.2328)
30. von Loeffelholz C, Mohlig M, Arafat AM, Isken F, Spranger J, Mai K, Randeva HS, Pfeiffer AF & Weickert MO. Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. European Journal of Endocrinology 2010 162 507-513. (doi:10.1530/EJE-09-0737)
31. Li Q, Chen R, Moriya J, Yamakawa J, Sumino H, Kanda T & Takahashi T. A novel adipocytokine, visceral adipose tissuederived serine protease inhibitor (vaspin), and obesity. Journal of International Medical Research 2008 36 625-629.
32. Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M & Bluher M. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008 57 372-377. (doi:10.2337/db07-1045)
33. Aust G, Richter O, Rohm S, Kerner C, Hauss J, Kloting N, Ruschke K, Kovacs P, Youn BS & Bluher M. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 2009 204 262-266. (doi:10.1016/j. atherosclerosis.2008.08.028)
34. Jeong E, Youn BS, Kim DW, Kim EH, Park JW, Namkoong C, Jeong JY, Yoon SY, Park JY, Lee KU & Kim MS. Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals. Journal of Clinical Endocrinology and Metabolism 2010 95 1869-1875. (doi:10.1210/jc.2009-1088)
35. Mantzoros CS, Liolios AD, Tritos NA, Kaklamani VG, Doulgerakis DE, Griveas I, Moses AC & Flier JS. Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men. Obesity Research 1998 6 179-186. (Pubitemid 128679659)
36. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M & Bluher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005 54 2911-2916. (doi:10.2337/diabetes. 54.10.2911)
37. Kloting N & Kloting I. Visfatin: gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats. Biochemical and Biophysical Research Communications 2005 332 1070-1072. (doi:10.1016/j.bbrc.2005.05.058)
38. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H & Li K. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Experimental and Clinical Endocrinology & Diabetes 2006 114 544-548. (doi:10.1055/s-2006- 948309)
39. Oki K, Yamane K, Kamei N, Nojima H & Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clinical Endocrinology 2007 67 796-800. (doi:10. 1111/j.1365-2265.2007.02966.x)
40. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G & Vettor R. Reduced plasma visfatin/ pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. Journal of Clinical Endocrinology and Metabolism 2006 91 3165-3170. (doi:10.1210/jc.2006-0361)
41. Garcia-Fuentes E, Garcia-Almeida JM, Garcia-Arnes J, Garcia- Serrano S, Rivas-Marin J, Gallego-Perales JL, Rojo-Martinez G, Garrido-Sanchez L, Bermudez-Silva FJ, Rodriguez de Fonseca F & Soriguer F. Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity 2007 15 2391-2395. (doi:10.1038/oby.2007.284)
42. Mitterberger MC, Mattesich M, Klaver E, Lechner S, Engelhardt T, Larcher L, Pierer G, Piza-Katzer H & Zwerschke W. Adipokine profile and insulin sensitivity in formerly obese women subjected to bariatric surgery or diet-induced long-term caloric restriction. Journals of gerontology. Series A, Biological sciences and medical sciences 2010 65 915-923. (doi:10.1093/gerona/ glq107)
43. Dostalova I, Sedlackova D, Papezova H, Nedvidkova J & Haluzik M. Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa. Physiological Research 2009 58 903-907.